Evan J. Lipson
Johns Hopkins University
H-index: 52
North America-United States
Top articles of Evan J. Lipson
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Comparing anti-tumor and anti-self immunity in a patient with melanoma receiving immune checkpoint blockade | Journal of translational medicine | Shuming Chen Tracee L McMiller Abha Soni Farah Succaria John-William Sidhom | 2024/3/5 |
Nivolumab+ Tacrolimus+ Prednisone±Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous Cancers | Journal of Clinical Oncology | Kara M Schenk Julie Stein Deutsch Sunandana Chandra Diwakar Davar Zeynep Eroglu | 2024/1/22 |
The obesity paradox in immune checkpoint blockade: A pan-tumor analysis | Cancer Research | Stephanie Leigh Alden Soren Charmsaz Madelena Brancati Howard L Li Aanika Warner | 2024/3/22 |
1575 Merkel cell carcinoma in solid organ transplant recipients: Baseline characteristics and response to immunotherapy | Journal of Investigative Dermatology | N Singh T Akaike A Fu K Cahill L Gunnell | 2023/5/1 |
Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO+ RELA) versus NIVO plus ipilimumab (NIVO+ IPI) in advanced melanoma: An indirect treatment comparison … | Dirk Schadendorf Hussein A Tawbi Evan J Lipson F Stephen Hodi Paolo Antonio Ascierto | 2023/6/1 | |
LBA51 Unraveling relatlimab (RELA)-specific biology using biomarker analyses in patients with advanced melanoma treated with nivolumab (NIVO)+ RELA or NIVO alone in RELATIVITY-047 | Annals of Oncology | EJ Lipson S Dolfi H Tang H Gogas HA Tawbi | 2023/10/1 |
Addressing barriers in care management, shared decision-making alignment, and educational needs on novel immunotherapy combinations in melanoma. | Tariqa Ackbarali Maria Arnone Megan Davis Schollenberger Omid Hamid Evan J Lipson | 2023/11 | |
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab | Journal of Clinical Oncology | Suzanne L Topalian Mario Sznol David F McDermott Harriet M Kluger Richard D Carvajal | 2023/2/10 |
589 Patients with advanced melanoma who benefit from the addition of anti-CTLA-4 to anti-PD-1 have a distinct tumor microenvironment (TME) | Journal of Investigative Dermatology | NM D'Amiano E Will JS Deutsch L Engle S Berry | 2023/5/1 |
Incidence, risk factors, and outcomes of immune-related adverse events (irAEs) in a prospective, pan-tumor population. | Aanika Balaji Stephanie Leigh Alden Howard Li Kabeer Munjal Evan J Lipson | 2023/6/1 | |
1024MO Interpretable AI-identified spatial tumor microenvironment (TME) neighborhoods associate with severe immune-related adverse events (irAE) and progressive disease (PD) in … | Annals of Oncology | D Jimenez-Sanchez EM Will J Lai G Warrier EJ Lipson | 2023/10/1 |
Neoadjuvant cemiplimab and surgery for stage II–IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study | The Lancet Oncology | Neil D Gross David M Miller Nikhil I Khushalani Vasu Divi Emily S Ruiz | 2023/11/1 |
Immune microenvironment of basal cell carcinoma and tumor regression following combined PD-1/LAG-3 blockade | Journal for immunotherapy of cancer | Julie Stein Deutsch Jonathan Lai Kara M Schenk Abha Soni Elizabeth M Will | 2023 |
190 Optimizing PD-1 to PD-L1 proximity assays to predict response in patients with advanced melanoma receiving anti-PD-1 | Journal of Investigative Dermatology | B Green E Will L Engle JS Deutsch E Lipson | 2023/5/1 |
Safety and clinical efficacy of immune checkpoint inhibition and stereotactic body radiotherapy in patients with spine metastasis | Journal of Neurosurgery: Spine | Emerson Lee Xuguang Chen Michael C LeCompte Lawrence R Kleinberg Russell K Hales | 2023/5/5 |
33P Impact of prior treatment on baseline immune biomarkers and nivolumab+ relatlimab (NIVO+ RELA)-induced changes in the tumor microenvironment (TME) in patients (pts) with … | Immuno-Oncology and Technology | PA Ascierto H Tang S Dolfi MS Nyakas IM Svane | 2023/12/1 |
Durable tumor regression and restoration of neurologic function after treatment with anti-PD-1 in patients with functionally unresectable cutaneous squamous cell carcinoma with … | Journal of neuro-oncology | Andrew R Carey Govind Warrier Jenny K Hoang Megan D Schollenberger Evan J Lipson | 2023/9 |
Proceedings from the Melanoma Research Foundation Mucosal Melanoma Meeting (December 16, 2022, New York, USA) | Alexander Z Wei Lanyi N Chen Marlana Orloff Charlotte E Ariyan Maryam Asgari | 2023/11 | |
Overall survival and response with nivolumab and relatlimab in advanced melanoma | NEJM evidence | Georgina V Long F Stephen Hodi Evan J Lipson Dirk Schadendorf Paolo A Ascierto | 2023/3/28 |
Nivolumab and relatlimab in patients with advanced melanoma that had progressed on anti–programmed death-1/programmed death ligand 1 therapy: Results from the phase I/IIa … | Journal of Clinical Oncology | Paolo Antonio Ascierto Evan J Lipson Reinhard Dummer James Larkin Georgina V Long | 2023/5/5 |
Co-Authors
